Unlike in the rest of the country, where intestinal ultrasound rarely is used in the clinic, in New York City, gastroenterologists at Mount Sinai Hospital have made IUS findings the “the fifth vital sign” for inflammatory bowel disease patient care, particularly to monitor disease. Now, new research from the institution and other centers is showing that the tool can identify patients with endoscopic recurrence and possibly predict disease outcomes and treatment response.
Trending
- SPY001, An Anti-α4β7, Shows Promise in Phase 2 SKYLINE Trial for Ulcerative Colitis (HCP Live)
- Recognizing and Treating Iron Deficiency Anemia in Gastrointestinal Disorders (GI & Endoscopy News)
- GLP-1s carry ‘far higher’ than expected risk for residual gastric content during endoscopy (Healio)
- Why GI is at the center of innovation — and what’s holding back the specialty (Becker’s GI & Endoscopy)
- AI remains lacking in clinical reasoning abilities, according to study of 21 large language models (Medical Xpress)
- The top 10 regulatory burdens for medical practices in 2026 (Physicians Practice)
- ctDNA Blood Tests in Colorectal Cancer Screening: High Specificity, Limited Detection of Precancerous Lesions (Healthcare in Europe)
- The Magnetic Flexible Endoscope: Phase 1 First-in-Human Clinical Trial (The American Journal of Gastroenterology)
